Skip to main content
. 2014 Jan;11(1):117–121. doi: 10.1513/AnnalsATS.201308-278OT

Table 3.

Summary of key recommendations

New research studies should include:
 1. Standardized measures for clinical and patient reported outcomes:
  Clinical outcomes can be reported as sputum conversion rate or cure and mortality rates at the end of treatment
  A range of patient-reported measures can be used: PREMs, PROMs, QALY, MOS-HIV Health Survey, and Karnofsky score
 2. Person-centered framework that acknowledges different comorbidities and treatment adverse events
 3. Strategies to minimize toxicity (e.g., intermittent administration)
 4. Cost-effectiveness and cost–benefit assessment
In addition, new research studies should enable:
 5. Data registries on clinical relevance and patient’s treatment and outcome to be commenced and easily populated
 6. Epidemiological/surveillance data on likelihood of adverse events to be made easily available to patients and health-care providers

Definition of abbreviations: MOS-HIV = Medical Outcomes Study HIV; PREMS = patient-reported experience measures; PROMS = patient-reported outcome measures; QALY = quality-adjusted life years.